Furthermore, N-Myc deregulation is implicated in other cancers like medulloblastoma, neuroendocrine prostate cancer, rhabdomyosarcoma, and AML 41, warranting further investigation into N78's efficacy against these N-Myc-driven malignancies. The gene discussed is MYCN; the disease is rhabdomyosarcoma.